Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?

References

• Crawford ED, Higano CS, Shore ND, et al. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194(6):1537–1547.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–131.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–2986.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351.
   PubMed Web of Science ®Google Scholar
• Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019. Eur Urol. 2020;77(4):508–547.
   PubMed Web of Science ®Google Scholar
• Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804.
   PubMed Web of Science ®Google Scholar
• Rosellini M, Santoni M, Mollica V, et al. Treating prostate cancer by antibody-drug conjugates. Int J Mol Sci. 2021;22(4):1551.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Mollica V, Cimadamore A, et al. Is there a role for immunotherapy in prostate cancer? Cells. 2020;9(9):2051.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Santoni M, Mollica V, et al. Microbiota and prostate cancer. Semin Cancer Biol. 2022;86:1058–1065.
   PubMedGoogle Scholar
• Grochtdreis T, König -H-H, Dobruschkin A, et al. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: a systematic review. PLoS ONE. 2018;13(12):1–25.
   Web of Science ®Google Scholar
• Norum J, Nieder C. Treatments for Metastatic Prostate Cancer (mPC): a review of costing evidence. PharmacoEconomics. 2017;35(12):1223–1236.
   PubMed Web of Science ®Google Scholar
• Massoudi M, Balk M, Yang H, et al. Number needed to treat and associated incremental costs of treatment with enzalutamide versus Abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. J Med Econ. 2017;20(2):121–128.
   PubMed Web of Science ®Google Scholar
• Wilson L, Tang J, Zhong L, et al. New therapeutic options in metastatic castration-resistant prostate cancer: can cost-effectiveness analysis help in treatment decisions? J Oncol Pract: official publication of the Inter J Oncol Pharm Pract. 2014;20(6):417–425.
   PubMed Web of Science ®Google Scholar
• Guirgis HM. The value of anticancer drugs in metastatic castrate-resistant prostate cancer: economic tools for the community oncologist. J Commun Support Oncol. 2015;13(10):362–366
   Google Scholar
• Pollard ME, Moskowitz AJ, Diefenbach MA, et al. Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. Asian J Urol. 2017;4(1):37–43.
   PubMed Web of Science ®Google Scholar
• Lebdai S, Basset V, Branchereau J, et al. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? World J Urol. 2016;34(5):617–624.
   PubMed Web of Science ®Google Scholar
• Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2018;75(1):88–99.
   PubMed Web of Science ®Google Scholar
• Garrison JLP, Neumann PJ, Erickson P, et al. Using real‐world data for coverage and payment decisions: the ISPOR real‐world data task force report. Value Health. 2007;10(5):326–335.
   PubMed Web of Science ®Google Scholar
• Akaza H, Procopio G, Pripatnanont C, et al. Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA prospective registry. J Glob Oncol. 2018;4(4):1–12.
   PubMedGoogle Scholar
• Angelergues A, Efstathiou E, Gyftaki R, et al. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel, Cabazitaxel, and Androgen Receptor-targeted Agents. Clin Genitourin Cancer. 2018;16(4): E777–84.
   Google Scholar
• Cheng HH, Gulati R, Azad A, et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with Abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis. 2015;18(2):122.
   PubMed Web of Science ®Google Scholar
• Oh WK, Cheng WY, Miao R, et al. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. Urol Oncol. 2018;36(500):e501–500. e509.
   Google Scholar
• Ellis LA, Lafeuille M-H, Gozalo L, et al. Treatment sequences and pharmacy costs of 2 new therapies for metastatic castration-resistant prostate cancer. Am Health Drug Benefits. 2015;8:185–194.
   PubMed Web of Science ®Google Scholar
• Koninckx M, Marco J, Pérez I, et al. Effectiveness, safety and cost of Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis. Clin Transl Oncol. 2019;21(3):314–323.
   PubMed Web of Science ®Google Scholar
• Schultz NM, Flanders SC, Wilson S, et al. Treatment duration, healthcare resource utilization, and costs among chemotherapy-naive patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: a retrospective claims analysis. Adv Ther. 2018;35(10):1639–1655.
   PubMed Web of Science ®Google Scholar
• Mahar RK, McGuinness MB, Chakraborty B, et al. A scoping review of studies using observational data to optimise dynamic treatment regimens. BMC Med Res Methodol. 2021;21(1):39.
   PubMed Web of Science ®Google Scholar
• eviQ Cancer Treatments Online. Cancer Institute New South Wales, New South Wales Government, Australia, viewed 20 October 2018. 2018.
   Google Scholar
• Lin D, Feuer E, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53(2):419–434.
   PubMed Web of Science ®Google Scholar
• Bang H, Tsiatis AAJB. Estimating medical costs with censored data. Biometrika. 2000;87(2):329–343.
   Web of Science ®Google Scholar
• Pfeifer PE, Bang Hjjo IM. Non-parametric estimation of mean customer lifetime value. Journal of Interactive Marketing. 2005;19:48–66.
   Google Scholar
• Zhao H, Tian LJB. On estimating medical cost and incremental cost‐effectiveness ratios with censored data. Biometrics. 2001;57(4):1002–1008.
   PubMed Web of Science ®Google Scholar
• Woldemichael A, Onukwugha E, Seal B, et al. Sequential therapies and the cost-effectiveness of treating metastatic colon cancer patients. J Oncol Pharm Pract. 2016;22(6):628–639.
   Google Scholar
• Krahn M, Bremner K, Luo J, et al. Long-term health care costs for prostate cancer patients on androgen deprivation therapy. Current Oncol (Toronto, Ont.). 2016;23(5):e443.
   PubMed Web of Science ®Google Scholar
• Boerty L, Broendum R, Boegsted M. ccostr: An R package for estimation of mean costs in censored data. Journal of Open Source Software. 2019;4(41):1593.
   Google Scholar
• Boegemann M, Khaksar S, Bera G, et al. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study. BMC Cancer. 2019;19(1):60.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Bhor M, Hennessy D, et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer. 2015;13(4):309–318.
   PubMed Web of Science ®Google Scholar
• Kreis K, Horenkamp-Sonntag D, Schneider U, et al. Treatment-related healthcare costs of metastatic castration-resistant prostate cancer in Germany: a claims data study. Pharmacoecon Open. 2020 Jun;5(2):299–310.
   Web of Science ®Google Scholar
• Padula WV, Kreif N, Vanness DJ, et al. Machine learning methods in health economics and outcomes research-The PALISADE checklist: a good practices report of an ISPOR task force. Value Health. 2022;25(7):1063–1080.
   PubMed Web of Science ®Google Scholar